Literature DB >> 27175979

Pseudomonas aeruginosa infection in cystic fibrosis: pathophysiological mechanisms and therapeutic approaches.

Helena Lund-Palau1, Andrew R Turnbull1,2, Andrew Bush2,3, Emmanuelle Bardin4, Loren Cameron5, Odel Soren6, Natasha Wierre-Gore3, Eric W F W Alton1, Jacob G Bundy3, Gary Connett7, Saul N Faust7, Alain Filloux8, Paul Freemont5, Andy Jones9, Valerie Khoo3, Sandra Morales10, Ronan Murphy1, Rishi Pabary1, Ameze Simbo1, Silke Schelenz11, Zoltan Takats4, Jeremy Webb11, Huw D Williams7, Jane C Davies1,2.   

Abstract

Pseudomonas aeruginosa is a remarkably versatile environmental bacterium with an extraordinary capacity to infect the cystic fibrosis (CF) lung. Infection with P. aeruginosa occurs early, and although eradication can be achieved following early detection, chronic infection occurs in over 60% of adults with CF. Chronic infection is associated with accelerated disease progression and increased mortality. Extensive research has revealed complex mechanisms by which P. aeruginosa adapts to and persists within the CF airway. Yet knowledge gaps remain, and prevention and treatment strategies are limited by the lack of sensitive detection methods and by a narrow armoury of antibiotics. Further developments in this field are urgently needed in order to improve morbidity and mortality in people with CF. Here, we summarize current knowledge of pathophysiological mechanisms underlying P. aeruginosa infection in CF. Established treatments are discussed, and an overview is offered of novel detection methods and therapeutic strategies in development.

Entities:  

Keywords:  Pseudomonas aeruginosa; airway; antibiotic; biofilm; cystic fibrosis; persistence; sputum

Mesh:

Substances:

Year:  2016        PMID: 27175979     DOI: 10.1080/17476348.2016.1177460

Source DB:  PubMed          Journal:  Expert Rev Respir Med        ISSN: 1747-6348            Impact factor:   3.772


  31 in total

1.  A 2.5-years within-patient evolution of a Pseudomonas aeruginosa with in vivo acquisition of ceftolozane-tazobactam and ceftazidime-avibactam resistance upon treatment.

Authors:  Thibaud Boulant; Agnès B Jousset; Rémy A Bonnin; Aurélie Barrail-Tran; Adrien Borgel; Saoussen Oueslati; Thierry Naas; Laurent Dortet
Journal:  Antimicrob Agents Chemother       Date:  2019-10-21       Impact factor: 5.191

Review 2.  Antimicrobial Resistance in ESKAPE Pathogens.

Authors:  David M P De Oliveira; Brian M Forde; Timothy J Kidd; Patrick N A Harris; Mark A Schembri; Scott A Beatson; David L Paterson; Mark J Walker
Journal:  Clin Microbiol Rev       Date:  2020-05-13       Impact factor: 26.132

3.  A panel of diverse Pseudomonas aeruginosa clinical isolates for research and development.

Authors:  Francois Lebreton; Erik Snesrud; Lindsey Hall; Emma Mills; Madeline Galac; Jason Stam; Ana Ong; Rosslyn Maybank; Yoon I Kwak; Sheila Johnson; Michael Julius; Melissa Ly; Brett Swierczewski; Paige E Waterman; Mary Hinkle; Anthony Jones; Emil Lesho; Jason W Bennett; Patrick McGann
Journal:  JAC Antimicrob Resist       Date:  2021-12-10

4.  Impact of Subinhibitory Concentrations of Metronidazole on Morphology, Motility, Biofilm Formation and Colonization of Clostridioides difficile.

Authors:  Tri-Hanh-Dung Doan; Marie-Françoise Bernet-Camard; Sandra Hoÿs; Claire Janoir; Séverine Péchiné
Journal:  Antibiotics (Basel)       Date:  2022-05-05

5.  Probability of Target Attainment of Tobramycin Treatment in Acute and Chronic Pseudomonas aeruginosa Lung Infection Based on Preclinical Population Pharmacokinetic Modeling.

Authors:  Bruna Bernar Dias; Fernando Carreño; Victória Etges Helfer; Priscila Martini Bernardi Garzella; Daiane Maria Fonseca de Lima; Fabiano Barreto; Bibiana Verlindo de Araújo; Teresa Dalla Costa
Journal:  Pharmaceutics       Date:  2022-06-11       Impact factor: 6.525

6.  How to Manage Pseudomonas aeruginosa Infections.

Authors:  Matthaios Papadimitriou-Olivgeris; Damien Jacot; Benoit Guery
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

7.  Detection of β-alanyl aminopeptidase as a biomarker for Pseudomonas aeruginosa in the sputum of patients with cystic fibrosis using exogenous volatile organic compound evolution.

Authors:  Ryan Thompson; Dominic Stephenson; Hannah E Sykes; John D Perry; Stephen P Stanforth; John R Dean
Journal:  RSC Adv       Date:  2020-03-12       Impact factor: 4.036

8.  Identification of FDA-Approved Drugs as Antivirulence Agents Targeting the pqs Quorum-Sensing System of Pseudomonas aeruginosa.

Authors:  Francesca D'Angelo; Valerio Baldelli; Nigel Halliday; Paolo Pantalone; Fabio Polticelli; Ersilia Fiscarelli; Paul Williams; Paolo Visca; Livia Leoni; Giordano Rampioni
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

9.  Expression of the MexXY Aminoglycoside Efflux Pump and Presence of an Aminoglycoside-Modifying Enzyme in Clinical Pseudomonas aeruginosa Isolates Are Highly Correlated.

Authors:  Alexander Seupt; Monika Schniederjans; Jürgen Tomasch; Susanne Häussler
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

10.  Biofilm Structures in a Mono-Associated Mouse Model of Clostridium difficile Infection.

Authors:  Anna P Soavelomandroso; Françoise Gaudin; Sandra Hoys; Valérie Nicolas; Gayatri Vedantam; Claire Janoir; Sylvie Bouttier
Journal:  Front Microbiol       Date:  2017-10-25       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.